Company Performance: Positive earnings reports, successful clinical trial results, and FDA approvals typically boost the stock price, while negative news can cause it to fall.

Market Sentiment: Overall investor optimism or pessimism towards the biotechnology sector or the stock market in general can influence AKBA.US's price.

Competition: The emergence of competing therapies or increased market share by competitors can negatively impact AKBA.US.

Regulatory Environment: Changes in regulations regarding drug approvals, pricing, or healthcare policies can affect investor confidence and the stock price.

Economic Conditions: Broad economic factors such as interest rates, inflation, and GDP growth can impact investor risk appetite and influence the stock's valuation.

News and Announcements: Company-specific news releases, industry conferences, and media reports can create short-term price volatility.

Analyst Ratings: Upgrades or downgrades by financial analysts can influence investor perception and trading activity.

Major Shareholders: Actions of large institutional investors, such as buying or selling significant blocks of shares, can impact supply and demand.

Technological Advancement: Breakthroughs in drug discovery or manufacturing processes could give AKBA.US a competitive advantage or disadvantage.

Mergers and Acquisitions: Rumors or actual mergers or acquisitions involving AKBA.US or its competitors can significantly affect the stock price.